isotretinoin

(redirected from Absorica)
Also found in: Dictionary.

isotretinoin

 [i″so-tret´ĭ-no-in]
a synthetic form of retinoic acid (13-cis-retinoic acid), used orally to clear cystic and conglobate acne.

i·so·tret·i·noin

(ī'sō-tret'i-noyn),
A retinoid used to treat severe recalcitrant cystic acne; a known human teratogen.

isotretinoin

(ī′sō-trĕt′n-oin′)
n.
A synthetic isomer of retinoic acid that inhibits sebaceous gland secretion and is used in the treatment of severe nodular acne. It can cause birth defects if taken during pregnancy.

isotretinoin

Retinoic acid, 13-cis retinoic acid A retinoid used to treat acne and psoriasis and may ↓ tumor development Side effects Inflammation of skin and mucosa, hepatitis

i·so·tret·i·no·in

(ī'sō-tret'i-nō'in)
A retinoid used to treat severe recalcitrant cystic acne; a known human teratogen.

isotretinoin

A RETINOID drug used to treat ACNE. The oral preparation is used under strictly controlled conditions to exclude pregnancy because of the known risks to the fetus. Brand names are Roaccutane, and, for external use Isotrex and Isotrexin.

Isotretinoin

A powerful vitamin A derivative used in the treatment of acne. It can promote scarring after skin resurfacing procedures.
Mentioned in: Acne, Skin Resurfacing

i·so·tret·i·no·in

(ī'sō-tret'i-nō'in)
A retinoid used to treat severe recalcitrant cystic acne; known human teratogen.
References in periodicals archive ?
Absorica royalty revenues in Q2 2019 were disappointing at $2.2 million compared to $3.8 million in Q2 2018.
The decrease in Adjusted EBITDA for Q2 2019 was driven by the decrease in Absorica royalties and to a lesser extent due to the timing of certain Clozaril orders in Canada.
Sun Pharma said the settlement has seen Ranbaxy, together with its partners, Cipher Pharmaceuticals and Galephar Pharmaceutical Research entering into a non-exclusive license deal with Actavis, allowing the New York-listed firm to start selling a generic version Absorica in the U.S.
Absorica, which is used for the treatment of severe recalcitrant nodular acne, a skin disease, in patients aged 12 years and more, presently has a market valued at $120 million in the United States.
Ranbaxy Laboratories Inc, a wholly owned subsidiary of Ranbaxy Laboratories Limited, announced yesterday that it has commenced a sales and promotion launch of Absorica (Isotretinoin) Capsules.
Absorica is indicated for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older.
Due to its high lipophilicity, oral absorption of isotretinoin is enhanced when given with a high-fat meal, however, Absorica, which is formulated using patented Lidose(r) technology, can be given without regards to meals.
Ashish Anvekar said, "We are most pleased to make Absorica available as a valuable option for dermatologists and a subset of patients who suffer from severe recalcitrant nodular acne.
Absorica is expected to be launched in the US in the fourth quarter of 2012.
The company said that the approval of Absorica represents its third US FDA approval and most important milestone to date.
"We are thrilled to make Absorica available as a valuable option for the dermatologists and patients who need treatment for severe recalcitrant nodular acne.
"Approval of Absorica represents our third FDA approval and most important milestone to date, reflecting the great work by our Scientific Affairs team at Cipher and our partner, Galephar Pharmaceutical Research," said Larry Andrews, President and CEO of Cipher.